5.74
price up icon11.24%   0.58
after-market アフターアワーズ: 5.74
loading
前日終値:
$5.16
開ける:
$5.12
24時間の取引高:
3.66M
Relative Volume:
2.53
時価総額:
$485.97M
収益:
$20.65M
当期純損益:
$-192.65M
株価収益率:
-1.8107
EPS:
-3.17
ネットキャッシュフロー:
$-134.39M
1週間 パフォーマンス:
+0.53%
1か月 パフォーマンス:
+26.15%
6か月 パフォーマンス:
+11.89%
1年 パフォーマンス:
-57.73%
1日の値動き範囲:
Value
$5.12
$5.76
1週間の範囲:
Value
$4.88
$5.76
52週間の値動き範囲:
Value
$4.305
$19.34

Verve Therapeutics Inc Stock (VERV) Company Profile

Name
名前
Verve Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
(978) 501-3026
Name
住所
201 BROOKLINE AVENUE, BOSTON
Name
職員
255
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
VERV's Discussions on Twitter

VERV を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VERV
Verve Therapeutics Inc
5.74 485.97M 20.65M -192.65M -134.39M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-04-08 開始されました H.C. Wainwright Buy
2023-04-13 開始されました Canaccord Genuity Buy
2023-02-01 開始されました Cantor Fitzgerald Neutral
2022-12-15 開始されました Goldman Sell
2022-10-06 開始されました Credit Suisse Neutral
2022-08-25 アップグレード Stifel Hold → Buy
2022-06-17 開始されました BMO Capital Markets Outperform
2022-02-18 開始されました RBC Capital Mkts Outperform
2021-09-24 開始されました Stifel Hold
2021-07-12 開始されました Guggenheim Buy
2021-07-12 開始されました JP Morgan Neutral
2021-07-12 開始されました Jefferies Buy
2021-07-12 開始されました William Blair Outperform
すべてを表示

Verve Therapeutics Inc (VERV) 最新ニュース

pulisher
Dec 19, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - The Eastern Progress Online

Dec 19, 2024
pulisher
Dec 19, 2024

Verve Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVERV - The Eastern Progress Online

Dec 19, 2024
pulisher
Dec 18, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online

Dec 18, 2024
pulisher
Dec 18, 2024

2024-12-18 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing

Dec 18, 2024
pulisher
Dec 18, 2024

Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation - AccessWire

Dec 18, 2024
pulisher
Dec 17, 2024

Verve Therapeutics Slides As Insider Purchases Lose Another US$65k - Yahoo Finance

Dec 17, 2024
pulisher
Dec 16, 2024

Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - The Eastern Progress Online

Dec 16, 2024
pulisher
Dec 16, 2024

Charles Schwab Investment Management Inc. Increases Stake in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat

Dec 16, 2024
pulisher
Dec 15, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out - AccessWire

Dec 15, 2024
pulisher
Dec 15, 2024

2024-12-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out | NDAQ:VERV | Press Release - Stockhouse Publishing

Dec 15, 2024
pulisher
Dec 14, 2024

Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact The Gross Law Firm - Victoria Advocate

Dec 14, 2024
pulisher
Dec 14, 2024

Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles - Investing.com India

Dec 14, 2024
pulisher
Dec 14, 2024

Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles By Investing.com - Investing.com Australia

Dec 14, 2024
pulisher
Dec 14, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - The Eastern Progress Online

Dec 14, 2024
pulisher
Dec 14, 2024

Verve Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before October 28, 2024 to Discuss Your RightsVERV - The Eastern Progress Online

Dec 14, 2024
pulisher
Dec 14, 2024

103,348 Shares in Verve Therapeutics, Inc. (NASDAQ:VERV) Purchased by XTX Topco Ltd - MarketBeat

Dec 14, 2024
pulisher
Dec 12, 2024

Pixalate Releases Q3 2024 EMEA Supply-Side Platform (SSP) Market Share Rankings for Connected TV (CTV), Mobile Apps, & Web: Magnite Leads CTV in Germany (65%) on Amazon Fire TV, Verve No. 1 on Mobile (57%) in Google Play Store - GlobeNewswire Inc.

Dec 12, 2024
pulisher
Dec 11, 2024

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 11, 2024

Shareholders that lost money on Verve Therapeutics, Inc.(VERV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 11, 2024

Faruqi & Faruqi Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 11, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 10, 2024

(VERV) On The My Stocks Page - Stock Traders Daily

Dec 10, 2024
pulisher
Dec 08, 2024

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth - Simply Wall St

Dec 08, 2024
pulisher
Dec 06, 2024

VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online

Dec 06, 2024
pulisher
Dec 06, 2024

Jacobs Levy Equity Management Inc. Increases Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat

Dec 06, 2024
pulisher
Dec 05, 2024

Redmile Group LLC Sells 80,040 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat

Dec 05, 2024
pulisher
Dec 03, 2024

Verve Therapeutics: Cutting-Edge Science But Highly Risky Stock - Seeking Alpha

Dec 03, 2024
pulisher
Dec 03, 2024

PDT Partners LLC Decreases Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat

Dec 03, 2024
pulisher
Dec 01, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. - GuruFocus.com

Dec 01, 2024

Verve Therapeutics Inc (VERV) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Verve Therapeutics Inc (VERV) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Kathiresan Sekar
Chief Executive Officer
Jun 28 '24
Option Exercise
2.87
30,000
86,100
351,128
Ashe Andrew D.
See Remarks
May 14 '24
Buy
6.26
76,000
475,760
342,509
Nickerson Joan
Chief Administrative Officer
Apr 02 '24
Sale
8.24
1,514
12,475
8,659
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):